Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Noncontrolling Interest [Abstract]
NCI – equity - December 31, 2023	$ 29,813
Net loss attributable to NCI	(3,300)	$ (4,283)
Impact of subsidiary equity transactions	1,734
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1	5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1	(24,295)
Lucid Diagnostics proceeds from issuance of preferred stock Series B	44,285
Lucid Diagnostics deemed dividend on preferred stock	(7,495)
Lucid Diagnostics 2018 Equity Plan stock option exercise	4
Lucid Diagnostics Employee Stock Purchase Plan Purchase	353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt	687
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan	744
Stock-based compensation expense - Veris Health 2021 Equity Plan	5
NCI – equity - March 31, 2024	$ 48,205